Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H35N6O9PS |
Molar mass | 626.62 g·mol−1 |
3D model ( JSmol) | |
| |
|
IDX-184 is an antiviral drug which was developed as a treatment for hepatitis C, acting as a NS5B RNA polymerase inhibitor. [1] [2] While it showed reasonable effectiveness in early clinical trials it did not progress past Phase IIb. [3] However research using this drug has continued as it shows potentially useful activity against other emerging viral diseases such as Zika virus, [4] [5] and coronaviruses including MERS, [6] and SARS-CoV-2. [7] [8]